Table II.
Targeted therapeutics for the EGFR/RAS/MAPK pathway.
| Inhibitor | Target | Function |
|---|---|---|
| Cetuximab | EGFR | EGFR inhibitor |
| Panitumumab | EGFR | EGFR inhibitor |
| Geftinib | EGFR | EGFR inhibitor |
| Sorafenib | RAF | Tyrosine kinase inhibitor |
| Pertuzumab | Her2 | Monoclonal antibody |
| Erlotinib | EGFR | Receptor Tyrosine kinase inhibitor |
| Lapatinib | EGFR, Her2 | Tyrosine kinase inhibitor |
| Dacomitinib | EGFR | Irreversible EGFR inhibitor |
| Canertinib (CI-1033) | EGFR, Her2, ErbB-4 | Irreversible tyrosine kinase inhibitor |
| Sunitinib | RTK2 | Receptor Tyrosine kinase inhibitor |
| PD158780 | EGFR, ErbB-3, ErbB-4 | Tyrosine kinase inhibitor |
| SCH772984 | ERK1/2 | ERK1/2 inhibitor |
| VX-11e | ERK2 | ERK2 inhibitor |
| Binimetinib | MEK1/2 | MEK1/2 inhibitor |
| Trastuzumab | HER2/neu | HER2 inhibitor |
| EMD72000 | EGFR | Monoclonal antibody for EGFR |
| Vemurafenib | BRAF-V600E | BRAF-V600E inhibitor |
| Dabrafenib | BRAF-V600E, C-RAF, BRAF | BRAF-V600E inhibitor |
| Encorafenib | BRAF-V600E | RAF inhibitor |
| Selumetinib | MEK1/2 | MEK1/2 inhibitor |